ArticleJournal for immunotherapy of cancer2022

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.

Laura Schäkel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.